This study aims to evaluate if a 6-month course of pancrelipase (CREON) treatment improves symptoms of exocrine pancreatic insufficiency (EPI) after an attack of acute pancreatitis. Diagnosis of EPI is measured by a fecal elastase value of <200, and patients must have a qualifying symptom burden based on the EPI symptom tracker survey. Blood and stool will be analyzed as part of this study, and other surveys of health status will be used to track improvement of symptoms.

开始日期2024-02-01

申办/合作机构

The Ohio State University

[+5]

NCT01682421

/ WithdrawnN/AIIT

Investigation of Treatment With Topical Corticosteroid After Posterior Lamellar Corneal Transplantation

After corneal transplantation, topical corticosteroids are used to reduce the risk of rejection.
However, the optimal postoperative treatment regimen is unknown. In most cases, a topical steroid is administered for at least 6 months after surgery, but it remains to be determined whether potent steroids offer better protection than weak steroids. Also, the length of the treatment is debated.
Since the use of steroids is not without potential serious ocular side effects, it is of considerable importance to investigate these problems.
The study aims to examine the frequency of rejection episodes after posterior lamellar keratoplasty; specifically comparing a short course of potent steroids versus a long course of weak steroids.

开始日期2012-09-01

申办/合作机构

Århus Universitetshospital

NCT01652157

/ TerminatedN/A

A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)

This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical care visits over a 10-year period and approached if they develop symptoms of fibrosing colonopathy for collection and use of further detailed information.

开始日期2012-07-31

申办/合作机构

AbbVie, Inc.

[+4]

100 项与胰脂肪酶(Eurand) 相关的临床结果

登录后查看更多信息

100 项与胰脂肪酶(Eurand) 相关的转化医学

登录后查看更多信息

100 项与胰脂肪酶(Eurand) 相关的专利（医药）

登录后查看更多信息

115

项与胰脂肪酶(Eurand) 相关的文献（医药）

2023-04-01·Journal of pharmacy practice

Efficacy of a Viokace Pancreatic Enzyme Protocol for Clearing Occluded Enteral Feeding Tubes: A Quality Assurance Evaluation

Article

作者: Kurish, Heena P. ; Stumpf, Janice L. ; Bruck, Cheryl L. ; Gabriel, Jacenta M.

Background: A previous retrospective study documented restored patency to 48.2% of occluded enteral feeding tubes using alkalinized Creon pancreatic enzyme capsules. In light of the low efficacy rate, the institutional enteral feeding tube clearance protocol was subsequently revised to incorporate a newly marketed non–enteric-coated Viokace pancreatic enzyme tablet, despite the lack of published data for this indication. Objective: This study aims to evaluate the effectiveness of a Viokace-based alkalinized pancreatic enzyme protocol to clear occluded enteral feeding tubes in a university health system. Methods: This retrospective, cohort quality assurance study included adult and pediatric patients receiving a Viokace-based pancreatic enzyme protocol for enteral feeding tube occlusions in a university health system during a 12-month period. The primary outcome was effectiveness in enteral tube clearance as documented in the electronic medical record. Efficacy of the new protocol was also compared with a Creon-based alkalinized solution using historical data. Results: The Viokace protocol successfully cleared 176 of the 277 (63.5%) occluded enteral feeding tubes occurring in 205 patients included in the analysis. The revised protocol was significantly more effective at clearing occluded enteral feeding tubes ( P = 0.0056) than a protocol using Creon pancreatic enzyme capsules. Conclusion: According to this retrospective evaluation, an alkalinized Viokace pancreatic enzyme protocol was effective in clearing 63.5% of occluded enteral feeding tubes. This significantly higher success rate than previously documented with a Creon-based protocol supports the change in pancreatic enzyme formulations in the institutional protocol.

2021-12-01·Addictive behaviors reports

Associations amongst form of cocaine used (powder vs crack vs both) and HIV-related outcomes

Article

作者: Cook, Robert L ; Liu, Yiyang ; Gebru, Nioud Mulugeta ; Spencer, Emma C ; Richards, Veronica L

INTRODUCTION:

Cocaine (including powder and crack) use is common among people with HIV (PWH). We identified socio-demographic and behavioral factors associated with cocaine use (overall and various forms) among PWH; we also examined differences in HIV treatment outcomes across cocaine exposure groups.

METHODS:

The study sample (N = 1166) was derived from two cohorts of PWH in Florida between 2014 and 2020. Baseline data were linked to the Enhanced HIV/AIDS Reporting System (eHARS) which tracks HIV viral load. Socio-demographics and polysubstance use were compared by cocaine use and the three cocaine use groups (powder only n = 101, crack only n = 91, or both n = 65). The association between the three cocaine use groups, ART adherence, and HIV viral suppression (<200 copies/mL) in the following year was assessed by multivariate logistic regression.

RESULTS:

People who used cocaine had lower HIV treatment adherence and viral suppression than those who did not use. People who used powder cocaine only were more likely to be younger, Hispanic/Latinx, and employed than those who used crack only or both. Compared to people who used both powder and crack cocaine, those who used one form of cocaine had 3 + odds of having durable viral suppression in the following year.

CONCLUSION:

The dual use of both powder and crack cocaine was associated with significantly worse HIV outcomes compared to use of only one form of cocaine. Screening for powder and crack cocaine use and timely intervention are needed to improve HIV treatment outcomes among this high-risk population.

2021-10-01·Journal of orthopaedic trauma3区 · 医学

Incidence of Surgical Site Infections and Acute Kidney Injuries After Topical Antibiotic Powder Application in Orthopaedic Trauma Surgery

3区 · 医学

Article

作者: Chu, Xiangquan ; Chambers, Lori ; Parry, Joshua A ; Mauffrey, Cyril ; Balabanova, Alla

OBJECTIVES:

To compare the incidence of deep surgical site infections (SSI) and acute kidney injuries (AKI) in patients who did and did not receive topical antibiotics during the open treatment of fractures.

DESIGN:

Retrospective comparative cohort.

SETTING:

Level 1 trauma center.

PATIENTS/PARTICIPANTS:

Three hundred ninety-six patients undergoing open fixation of fractures.

INTERVENTION:

The topical antibiotic group included 78 (20%) patients. Vancomycin only was used in 28 (7%) patients with the median dose (interquartile range) of 1 g (1-2 g) and vancomycin/tobramycin was used in 48 (12%) patients with a median dose (interquartile range) of 2 g (1-2 g)/1.2 g (1.2-1.2 g).

MAIN OUTCOME MEASUREMENTS:

Deep SSI requiring debridement and AKI (>50% increase in creatinine compared with preoperative level).

RESULTS:

There was no detectable difference in SSI between the topical antibiotic and control groups (13% vs. 10%, odds ratio (OR) 1.3, 95% confidence interval (CI) 0.6 to 2.9). Variables associated with SSI on multivariate analysis included open fracture (OR 3.2, CI 1.5 to 6.5) and an American Society of Anesthesiologists classification of >2 (OR 2.7, CI 1.3 to 5.3). There was no detectable difference in AKI between the topical antibiotic and control groups (1 (2%) vs. 7 (5%); OR 0.3, CI 0.04 to 3).

CONCLUSION:

There was no detectable difference, with wide confidence intervals, in SSI and AKI between the topical antibiotic and control groups. Further studies need to be conducted to evaluate the relationship between topical antibiotics and clinical outcomes in orthopaedic trauma surgery.

LEVEL OF EVIDENCE:

Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

项与胰脂肪酶(Eurand) 相关的新闻（医药）

2022-07-08

·BioSpace

Report: Merck in Advanced Talks to Acquire Seagen for $40B

Merck is in late-stage discussions to acquire Seagen for about $40 billion, sources told The Wall Street Journal. Seagen is an appealing oncology target for Merck at a time when the latter is looking to bolster its cancer portfolio as mega-blockbuster Keytruda (pembrolizumab) teeters on the patent cliff. The WSJ report suggests Merck is offering more than $200 per share and hopes to close the deal on or before its quarterly earnings report on July 28. On Wednesday, Seagen’s stock closed at $175.13 per share. Rumors about the talks have been ongoing for several weeks. Seagen’s market cap is above $32 billion. In September 2020, the two companies inked a co-development pact to advance ladiratuzumab vedotin, a potential cancer therapy. Merck threw $600 million into the deal up front and acquired 5 million shares of Seagen stock for $1 billion. They also have a licensing deal for Tukysa in countries outside the U.S., Canada and Europe, for which Merck paid $125 million at the outset. Merck’s Keytruda, an anti-PD-1 checkpoint inhibitor, brought in $7.2 billion last year alone. In Q1 this year, the drug raked in $4.7 billion, up 23% from last year over the same period. Keytruda will lose exclusivity in 2028. Last year it made up 35.2% of Merck’s total revenue. Seagen’s focus is on antibody-drug conjugates (ADCs). These therapies link cancer-specific antibodies to cancer toxins. Its best-known drug is Adcetris. Merck is one of the top oncology companies in the world but doesn’t have much of a focus on ADCs. Its market cap is $233 billion. In a note to investors in June, Wells Fargo analyst Mohit Bansal wrote, “The real value to MRK (Merck) is qualitative as SEGEN (Seagen) adds durability and diversity to the company beyond Keytruda,” according to Seeking Alpha. If Merck and Seagen do close on a deal, they can expect regulators to take a close look. The U.S. Securities and Exchange Commission has increased its scrutiny of larger mergers and is taking a hard look at competing products, sometimes forcing companies to divest drugs before the deal is approved. As an example, in 2020, when AbbVie acquired Allergan, the SEC and other regulators required the companies to divest brazikumab and Zenpep (pancrelipase). If they do manage to pull the deal together, it will be the largest life science M&A activity for the year to date. So far, the largest deal has been Pfizer’s acquisition of Biohaven for $11.6 billion. It’s been a relatively quiet year, with M&A activity in the sector down 58% compared to the first half of 2021, with a valuation of $61.7 billion. In the first half of this year, there have been 137 deals, down 33% from the same period in 2021. Other deals include Bristol Myers Squibb’s acquisition of Turning Point Therapeutics for $4.1 billion, GSK's takeover of Affinavax for $3.3 billion and Biocon Biologics’ acquisition of Viatris’ biosimilar portfolio and related commercial and operational capabilities for $3.3 billion. There are numerous factors behind the slow M&A market, including ongoing supply chain problems, inflation, political uncertainty globally with the Russia-Ukraine war, and higher input costs, especially around packaging, due to inflationary pressures. Still, many biopharma companies have plenty of cash, especially if they have had any COVID-19-related products approved over the last two years. A recent PwC report noted that “pharma is in a good position to combat this issue as most companies have plenty of cash on hand and can take more risks by purchasing early-stage assets. With capital becoming harder to come by for most biotechs, pharma is in a good position to acquire many of these companies at a discount from their highs of just a couple of years ago.”

并购抗体生物类似药抗体药物偶联物

2022-06-24

·BioSpace

Merck, Seagen Talks Heat Up Under Cloud of Regulatory Scrutiny

Kena Betancur/Getty Images Talks between Merck and Seagen are heating up as the former looks to buy the latter, according to a report from The Wall Street Journal. If the merger-and-acquisition deal did go through, it would likely be a sizable one, since Seagen has a market cap above $32 billion. This follows last week’s report published by WSJ that stated Merck was exploring purchasing the biotech company. In September 2020, Merck and Seagen entered into an agreement to co-develop ladiratuzumab vedotincancer, a cancer treatment, with Merck pitching in $600 million upfront and acquiring 5 million shares of Seagen stock for $1 billion. They also have a licensing deal for Tukysa in countries outside the U.S., Canada and Europe, and Merck dropped $125 million upfront for that cancer drug. Both companies are strong players in the oncology space. Merck’s lead product is its blockbuster anti-PD-1 checkpoint inhibitor Keytruda (pembrolizumab). The drug brought in $17.2 billion in 2021 alone. In the first quarter of this year, Keytruda brought in $4.7 billion, an increase of 23% from the previous year. Seagen focuses on antibody-drug conjugates (ADCs). These drugs have onco-toxins attached to an antibody that delivers the drugs directly to the tumors. Its best-known drug is Adcetris. On June 6, Seagen and Genmab announced interim data from the innovaTV 205 trial of Tivdak (tisotumab vedotin) in combination with Keytruda in patients with recurrent or metastatic cervical cancer who have not received previous systemic therapy. The interim data demonstrated a confirmed objective response rate (ORR) of 41% and median durability of response that was not achieved within almost 19 months of median follow-up. Tivdak is an ADC made up of Genmab’s human monoclonal antibody directed to tissue factor (TF) and Seagen’s ADC technology. “With Genmab, we will continue to investigate tisotumab vedotin in combination with other therapies because there is still an unmet need for more effective first-line treatment for advanced cervical cancer patients,” Marjorie Green, M.D., senior vice president and head of late-stage development at Seagen, said in a statement. “We’re also researching innovative new tools to help increase awareness of the disparities and unmet needs that cervical cancer patients experience in order to better support this community in the future.” Although Merck is a powerhouse in the oncology space, it doesn’t really focus on ADCs. It has a significantly larger market cap than Seagen, at about $233 billion. According to Seeking Alpha, Seagen's shares have risen considerably since the WSJ report, and Wells Fargo analyst Mohit Bansal wrote in a note that the value of a deal would be within the $200-$220/share range. "The real value to MRK (Merck) is qualitative as SGEN (Seagen) adds durability and diversity to the company beyond Keytruda," Bansal said in the note obtained by Seeking Alpha. Although picking up Seagen would certainly beef up its already strong oncology portfolio, Merck is reportedly concerned that regulators might block the deal. The Securities and Exchange Commission has taken a close look at competing products with merging companies, sometimes forcing companies to divest drugs for the deals to go through. For example, in 2020, when AbbVie acquired Allergan, regulators required the companies to divest brazikumab and Zenpep (pancrelipase). A recent report on the industry by PwC notes that one of the reasons M&A activity has been so slow this year is concern over increased regulatory scrutiny. On the other hand, a driving factor for M&A interest is an increasing number of patent expirations. Although Keytruda is still growing, its patents start to expire in 2028. Keytruda has been approved for a long list of cancer indications, both as a monotherapy and in combination with numerous other cancer drugs. Amidst all of this, Seagen is undergoing some changes. In May, the company’s president, CEO and board member, Clay Siegall, resigned after domestic violence allegations, which had resulted in a leave of absence earlier in the month. The board is currently conducting a search for a replacement. Meanwhile, Roger Dansey, M.D., the company’s chief medical officer, is acting as interim CEO.

抗体抗体药物偶联物并购专利到期

2022-06-13

·药通社

DSC在药学中的应用

差示扫描量热法（DSC），在程序控制温度下, 测量输给物质与参比物的功率差与温度的一种技术。因其操作简便快速，无需添加溶剂，样品用量少，图谱易懂等优点，被广泛应用于药物的研发和生产等领域。差示扫描量热仪可以测定多种热力学和动力学参数，如比热容、反应热、转变热、相图、反应速率、结晶速率、高聚物结晶度、样品纯度等。1药物的鉴别当物质被加热时会发生熔化、升华等相变，相变所需热量与样品的量成正比，每种物质的相变温度或发生分解时的热效应是固定的，其DSC图谱也是特定的，因此DSC可用于药物的鉴别。如上图为感冒灵胶囊（由扑热息痛、咖啡因、苯丙醇和扑尔敏组成的复方制剂）的DSC曲线图，从图中可以该胶囊在123℃、132℃、161℃和221℃有4个熔点峰，并且当温度超过230℃时，开始发生分解。因为特定成分和比例的药品的DSC图谱是一定的，因此可以用此鉴别假药或冒牌药。2药物纯度的测定测定纯度的方法有液相色谱法、紫外光谱法、红外光谱法和滴定法等，最常用方法为高效液相色谱法，但当色谱法分离效果有限或者样品含有未知杂质而其检测响应值存在差异时，则无法准确测定杂质的含量。与传统的 HPLC法纯度分析相比，基于热动力学原理的DSC 纯度分析法（依据范德霍夫方程) 利用物质的 DSC 熔融曲线，计算该物质的杂质含量，没有繁琐的样品前处理过程，也无需寻找适宜的标准物质、溶剂，该方法简便、快速，更适合高纯度物质分析，所需样品量少，因此适用于化学药品对照品的纯度研究。下表为7种药物通过DSC及其纯度测试软件得到的纯度结果。因为物质的熔融行为受杂质的影响，多数有机物会发生低共熔，其中杂质含量越多，熔点越低，熔程越宽。正如下图所示，某分析级药物的熔融峰较工业级该药物的峰形尖锐。但是注意DSC测定样品纯度的前提是样品热力学要稳定，具有单一的熔融吸热峰，若样品发生熔融分解或挥发无明显熔融吸热峰时，则不适用于DSC纯度分析。3多晶态的分析由于药物的晶型不同，其晶格能不同导致熔点也会有差异，DSC图谱也会不同，一般来说: 在热力学上稳定性较差的晶型往往具有较低的熔点。（1）判断药物存在状态下图为3种晶型异丙双酚的DSC曲线图，可以看出3种晶型的DSC图有较大差异，可以用于区分3种晶型。（2) 晶型转变过程此外，DSC图谱还可提供其热力学变化过程，发现各晶型转变，为选择转晶条件提供依据，如从下图可以看出某药物的两种晶型的转变过程。(3) 结晶度的定量左图为他克莫司、HPMC、HPMC与他克莫司 1:1 物理混合物 (SD1) 、 1:1 SD 制剂 (SD6) ，以及不同结晶比例的SD2- SD6的DSC曲线图。右图是通过左图中不同结晶比例的 SD 样品的结晶百分比，熔化热的百分比数据的拟合图，进而可以通过DSC图谱上的熔化热的百分比来确定他克莫司的结晶度。4药物的稳定性研究药物的稳定性可以为存储、制备工艺与质量控制提供依据。（1）蛋白质的热稳定性考察上图为1mg/ml的溶菌酶在(a) pH 4.0 醋酸盐缓冲液、(b) pH 2.5 甘氨酸缓冲液和 (c) pH 7.4 PBS的DSC曲线。发现溶菌酶在 pH 4.0 醋酸盐和 pH 2.5 甘氨酸盐中构象稳定，具有良好的稳定性，但是在 pH7.4 磷酸盐中，溶菌酶随着温度的升高有聚合的趋势。（2）光照稳定性考察上图为葡萄糖酸锌在不同光照时间下的DSC曲线峰形图，由图可知：当葡萄糖酸锌在光照7小时后, DSC曲线峰温及峰形开始发生变化，这说明葡萄糖酸锌的光稳定性较差。5药物与辅料的兼容性通过比较药物、辅料二元或多元混合物与单一物质的 DSC 曲线比较吸热、放热特征峰的偏移、消失、焓值等变化，判断药物和辅料间、或药物与药物间有无物理化学作用，为辅料的选择提供依据。上图为卡托普利与各种辅料的1：1物理混合物的DSC曲线图，其中曲线1-卡托普利，2-卡托普利+CMC101 ，3-卡托普利+CMC102， 4-卡托普利+乙基纤维素，5-卡托普利+甲基纤维素。上图中曲线1-卡托普利，2-卡托普利+一水乳糖，3-卡托普利+乳糖Supertab®，4-卡托普利+硬脂酸镁，5-卡托普利+硬脂酸。从上面的两个曲线图可以发现不同种类的微晶纤维素、乳糖、乙基纤维素等与卡托普利混合后 DSC 图谱是两者的叠加，说明卡托普利与这些辅料的相容性良好，但与硬脂酸镁的混合物71-109℃范围内有两个吸热峰，这是硬脂酸镁脱水过程的特征。卡托普利的熔融峰消失表明卡托普利与硬脂酸镁不能相容。6冻干与喷雾干燥等工艺优化（1）冻干-退火升华干燥前可以将搁板温度提高到玻璃转化温度Tg之上，并保持设定的时间进行退火操作，强化结晶，提高非晶相最大浓缩液的玻璃化温度；还可以改变冰晶大小分布与形态，加快干燥。（2）热熔挤出固体分散体-挤出温度热熔挤出技术制备固体分散体时，载体的玻璃转化温度Tg值应较低, 这样才有一定的操作性，挤出设置温度应高于Tg 20~30℃，以保证载体良好的流动性，但是要低于药物与载体的分解点以保持稳定性。（3）喷雾干燥进行喷雾干燥时，要料液的玻璃化转变温度Tg，进而控制最终产品质量。7研究皮肤透过机理采用 DSC法对胰脂肪酶处理前后的皮肤进行解析，研究其对水溶性大分子的透皮吸收促进机理。结果经胰脂肪酶处理的皮肤，角质层中排列整齐的脂质产生吸热峰发生明显变化，这说明胰脂肪酶可能直接作用于皮肤角质层的脂质部分，使其结晶排列状态发生变化、部分溶解或转变为无序状态，进而促进药物的透皮吸收[7]。参考文献：1.STULZER K H, RODRIGUESOP, CARDOSOMT, et al. Compatibility studies between captopril and pharmaceutical excipients used in tablets formulations [J]. J Therm Anal Calorimetry, 2008, 91(1): 323-328.2.刘毅等，差示扫描量热法在化学药品对照品纯度分析中的应用[J].，Chinese Journal of New Drugs 2017,26(10).3.吴锐等，化学药品标准物质DSC纯度的应用性规律探讨[J].，药物分析杂志，Chin J Pharm Anal 2020,40(8).4.于颖，用差动热分析法 (DSC) 测定葡萄糖酸锌的稳定性.5.刘婕等，差示扫描量热技术在药剂学中的应用进展[J]，中国药剂学杂志 2017,15(5)。6. ZIDAN A S, RAHMAN Z, SAYEED V, et al. Crystallinity evaluation of tacrolimus solid dispersions by chemometric analysis[J]. Int J Pharm, 2012, 423(2): 341-350.7.TIAN Y, BOOTH J, MEEHAN E, et al. Construction of drug−polymer thermodynamic phase diagrams using flory−huggins interaction theory: Identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions [J]. Mol Pharm, 2013, 10: 236-248.药事纵横投稿须知：稿费已上调，欢迎投稿

100 项与胰脂肪酶(Eurand) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A09AA02	DB00085

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胰腺外分泌功能不全	美国	Eurand Pharmaceuticals, Inc.	2009-08-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性胰腺炎	临床3期	美国	Forest Laboratories LLC	2007-11-01
慢性胰腺炎	临床3期	加拿大	Forest Laboratories LLC	2007-11-01
慢性胰腺炎	临床3期	波兰	Forest Laboratories LLC	2007-11-01
慢性胰腺炎	临床3期	斯洛伐克	Forest Laboratories LLC	2007-11-01
脂肪泻	临床3期	美国	Forest Laboratories LLC	2006-11-01
囊性纤维化	临床3期	美国	Forest Laboratories LLC	2006-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00880100 (CTgov)	临床3期	脂肪泻 \| 胰腺外分泌功能不全 \| 囊性纤维化	49	Ultrase® MT12	齋範艱齋鹹鏇憲鏇膚憲(餘範繭鬱鹹簾簾餘糧構) = 積襯鹹鏇鏇壓製遞餘廠膚鹽觸選鑰餘觸網遞糧 (蓋鏇築構獵遞築鑰構選, 繭蓋夢顧繭鏇鏇鹽顧築 ~ 夢構廠鹹構繭願蓋顧觸) 更多	-	2015-02-19
NCT01327703 (CTgov)	临床4期	脂肪泻 \| 囊性纤维化 \| 胰腺外分泌功能不全	87	Panzytrat (Panzytrat®)	鏇夢獵積鑰壓糧鬱觸簾(積築範夢淵鬱蓋鹹襯齋) = 築淵窪憲齋艱鹽觸積膚鹹襯繭網鹽顧糧壓鹽製 (夢鑰鹹網醖積積鹽鬱醖, 衊艱簾廠範獵餘願鹹艱 ~ 遞憲繭餘窪繭遞鹹鬱獵) 更多	-	2014-04-10
				Kreon (Kreon®)	鏇夢獵積鑰壓糧鬱觸簾(積築範夢淵鬱蓋鹹襯齋) = 築鏇夢醖繭製膚醖醖願鹹襯繭網鹽顧糧壓鹽製 (夢鑰鹹網醖積積鹽鬱醖, 選繭廠衊簾淵顧遞齋願 ~ 窪壓鑰遞鑰製製糧構壓) 更多
NCT01100606 (CTgov)	临床4期	囊性纤维化 \| 胰腺外分泌功能不全	15	EUR-1008 (APT-1008) (EUR-1008 (APT-1008) in Apple Juice)	鹹膚膚餘顧鹹鬱鑰鹹襯(餘選艱鹹餘鬱築鏇蓋繭) = 廠衊艱願製夢鬱遞壓觸蓋鑰繭蓋積簾廠築繭鏇 (窪廠廠蓋壓積選膚齋選, 艱醖壓鬱簾餘壓鏇艱鹹 ~ 夢醖網窪築構獵鑰築鹹) 更多	-	2014-04-10
				EUR-1008 (APT-1008) (EUR-1008 (APT-1008) in Apple Sauce)	鹹膚膚餘顧鹹鬱鑰鹹襯(餘選艱鹹餘鬱築鏇蓋繭) = 製憲築鏇廠衊醖夢網簾蓋鑰繭蓋積簾廠築繭鏇 (窪廠廠蓋壓積選膚齋選, 築願憲鑰鏇壓鑰範齋築 ~ 鹹襯積夢製觸顧繭鑰艱) 更多
NCT00981214 (CTgov)	临床3期	胰腺外分泌功能不全 \| 囊性纤维化	19	EUR-1008 (APT-1008)	鹽鏇築艱餘窪遞齋獵艱(網齋願壓製齋壓憲獵觸) = 構範艱積淵醖壓淵獵齋餘壓艱壓膚壓製構憲鹽 (齋鹽蓋鹽齋獵鑰憲鏇壓, 繭衊壓醖製廠遞繭窪鑰 ~ 構鹹窪網窪鏇襯鑰餘齋) 更多	-	2014-04-04
NCT00408317 (CTgov)	临床3期	脂肪泻 \| 囊性纤维化 \| 胰腺外分泌功能不全	36	Ultrase® MT20 (Ultrase® MT20)	鑰獵醖蓋選鏇繭衊齋積(齋鬱餘餘築鬱鹹顧簾選) = 鏇構鬱膚繭製積夢積憲壓夢餘製憲鬱壓範艱襯 (鹽廠鹽觸夢網餘繭淵糧, 餘膚觸艱製壓獵願築積 ~ 鏇蓋顧淵鑰齋鹹淵網鏇) 更多	-	2014-03-12
				Placebo (Placebo)	鑰獵醖蓋選鏇繭衊齋積(齋鬱餘餘築鬱鹹顧簾選) = 齋壓鬱憲鹽觸構鏇壓淵壓夢餘製憲鬱壓範艱襯 (鹽廠鹽觸夢網餘繭淵糧, 艱簾願願壓構鹽築壓築 ~ 憲醖鹹簾簾築餘鑰遞觸) 更多
NCT00788593 (CTgov)	临床3期	慢性胰腺炎 \| 胰腺外分泌功能不全	82	EUR-1008 (APT-1008) Low Dose (EUR-1008 (APT-1008) Low Dose)	遞餘膚網廠夢鹽顧鹽膚(鏇窪鹽顧襯壓餘壓構夢) = 繭糧獵艱觸築夢壓鬱齋壓顧築衊糧構鹽繭觸蓋 (顧鹹壓膚醖糧鹽築鹹願, 獵網夢壓糧範蓋網鏇鑰 ~ 膚構夢窪製鏇醖衊窪遞) 更多	-	2014-03-12
				EUR-1008 (APT-1008) High Dose (EUR-1008 (APT-1008) High Dose)	遞餘膚網廠夢鹽顧鹽膚(鏇窪鹽顧襯壓餘壓構夢) = 窪簾範簾鑰糧蓋襯窪窪壓顧築衊糧構鹽繭觸蓋 (顧鹹壓膚醖糧鹽築鹹願, 製鬱餘築範廠繭鬱窪醖 ~ 鏇構糧構範衊製衊構齋) 更多
NCT00559364 (CTgov)	临床3期	慢性胰腺炎 \| 脂肪泻 \| 胰腺外分泌功能不全	50	Proton pump inhibitor (PPI)+Omeprazole	鑰製觸齋鏇窪繭鬱繭簾(衊窪鹽鏇鏇窪網顧蓋壓) = 壓構遞襯獵鏇遞艱齋衊遞顧衊衊艱觸齋艱築膚 (襯淵遞夢構壓淵鏇觸淵, 廠願遞壓壓壓構膚鹹餘 ~ 齋餘網簾襯構積夢衊鹽) 更多	-	2014-03-12
NCT01131507 (PR-018, CTgov)	临床4期	胰腺外分泌功能不全 \| 囊性纤维化	15	EUR-1008 (APT-1008)	餘齋獵壓獵顧顧觸淵鏇(觸蓋築膚餘壓願範壓構) = 願艱襯鹹構襯淵鹹艱鹹觸願餘齋膚齋簾蓋餘鹹 (簾廠觸製鑰衊網製齋餘, 衊獵憲選鹽齋鹽憲範糧 ~ 獵繭範積觸壓艱艱齋衊) 更多	-	2014-03-07